Key result
Integrating clinical parameters with new potential biomarkers may improve the predictive power of the CHA2DS2-VASc score for thromboembolic risk in atrial fibrillation.
Why the study?
The CHA2DS2-VASc score is not a perfect instrument for assessing stroke risk in atrial fibrillation, motivating the exploration of biomarkers to improve its predictive power.
Can the integration of new biomarkers with the CHA2DS2-VASc score improve the prediction of thromboembolic risk in patients with atrial fibrillation?
Can the integration of new biomarkers with the CHA2DS2-VASc score improve the prediction of thromboembolic risk in patients with atrial fibrillation?
Integrating new biomarkers with established clinical scores like CHA2DS2-VASc may improve the accuracy of thromboembolic risk stratification in atrial fibrillation.
Ischemic stroke risk in atrial fibrillation differs from patient to patient, depending on numerous variables. Many attempts have been made to translate this difference into simple numbers and to compare it to the hemorrhagic risk of anticoagulation. Different clinical scores have been studied to define a clear strategy. One score, the CHA2DS2-VASc score, has been extensively and successfully applied worldwide. Nevertheless, it is not yet the “perfect instrument”. Many proposals have been made to integrate its clinical parameters with some biomarkers to improve its predictive power. This short review describes some of these biomarkers and their possible implications in potentiating the efficacy of clinical scores.
No takes yet. Share an insight, caveat, or question.
Pezzo et al. (2022) conducted a review in Atrial fibrillation. Biomarkers was evaluated. Integrating clinical parameters with new potential biomarkers may improve the predictive power of the CHA2DS2-VASc score for thromboembolic risk in atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: